Theoretical Evaluation of Twenty Cannabinoid Derivatives on Androgen Receptor or 5α-Reductase Enzyme
January 2023
in “
Clinical cancer investigation journal
”
TLDR Some cannabinoid derivatives may be more effective than current drugs at targeting proteins relevant to prostate cancer treatment.
The theoretical research evaluated the interaction of twenty cannabinoid derivatives with either androgen receptor or 5a-reductase enzyme. The results showed that cannabinoid derivatives 6, 13, 16, and 20 had higher affinity for the androgen receptor surface compared to testosterone, dihydrotestosterone, and flutamide. Additionally, cannabinoid derivatives 1, 3, 14, and 18 showed higher affinity for the 5a-reductase enzyme compared to dutasteride and finasteride. This suggests that these cannabinoid derivatives could act as androgen receptor inhibitors and 5a-reductase enzyme inhibitors, making them potential candidates for the treatment of prostate cancer.
